Biotechnology

WuXi Biologics Receives MSCI AAA ESG Rating for Third Consecutive Year

SHANGHAI, Oct. 9, 2025 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), announced it has received the esteemed AAA ESG rating from Morgan Stanley Capital International (MSCI) for the third consecutive year. This to...

2025-10-10 08:30 1111

Celltrion receives U.S. FDA approval for EYDENZELT® (aflibercept-boav), biosimilar referencing EYLEA® (aflibercept)

* EYDENZELT® is approved for the treatment of patients with neovascular (wet) age-related macular degeneration (wAMD), macular edema following retinal vein occlusion (RVO), diabetic macular edema (DME), and diabetic retinopathy (DR) * Celltrion plans to enter the U.S. ophthalmology market to m...

2025-10-10 06:56 1379

Alamar Biosciences Launches NULISAqpcr™ BD-pTau217 Assay: A Breakthrough in Non-Invasive, Brain-Specific Biomarker Detection for Alzheimer's Disease Research

New Blood-Based Assay Delivers Unparalleled Sensitivity and Specificity to enable the next generation of assay development.  FREMONT, Calif., Oct. 10, 2025 /PRNewswire/ -- Alamar Biosciences, a company powering precision proteomics to enable the earliest detection of disease, today announced the...

2025-10-10 05:23 1273

Lifespan-Backed Algen Biotechnologies Partners with AstraZeneca to Advance AI Drug Discovery

NORWALK, Conn., Oct. 9, 2025 /PRNewswire/ -- Lifespan Vision Ventures congratulates its portfolio company, Algen Biotechnologies, on the announcement of its multi-target research collaboration with AstraZeneca to advance AI-powered drug discovery in immunology. The partnership will combine Algen...

2025-10-09 23:09 1108

LuX-Valve Plus Approved for Hong Kong-Macao Medicine and Equipment Connect

BEIJING, Oct. 9, 2025 /PRNewswire/ -- Jenscare Scientific Co., Ltd. ("Jenscare" or the "Company") (HKEX: 9877), an innovative medical device company with comprehensive structural heart disease interventional solutions, recently announced that LuX-Valve Plus transjugular tricuspid valve replacemen...

2025-10-09 21:00 1261

Phase 3 Clinical Trial of HANSIZHUANG Plus Chemotherapy Meets Primary Endpoint in Neoadjuvant/Adjuvant Gastric Cancer, Greenlighting Early NDA Submission

* The phase 3 clinical trial of HANSIZHUANG for perioperative gastric cancer treatment met its EFS primary endpoint, supporting an early New Drug Application (NDA) submission * World-first regimen in gastric cancer that replaces adjuvant chemotherapy with mono-immunotherapy in the perioperati...

2025-10-09 20:50 1481

Samsung Biologics Introduces Optimized Manufacturing Framework, ExellenS™

* ExellenS TM applies optimized facility designs, equipment, and processes across all sites to ensure equivalency and speed * ExellenS TM combines the company's commitment to operational excellence with its core manufacturing competencies, guided by standardization, simplification, and scalab...

2025-10-09 19:00 1178

Chance Pharma Announces Commercialization Agreement with Huadong Medicine for Innovative Respiratory Drug CXG87

HANGZHOU, China, Oct. 9, 2025 /PRNewswire/ -- Chance Pharmaceuticals ("Chance" or "Chance Pharma"), a clinical-stage biotechnology company dedicated to the research and development of innovative inhalation therapies, today announced that it has reached an exclusive commercialization agreement wit...

2025-10-09 17:27 1251

Everest Medicines Announces Publication of Etrasimod's Asian Multicenter Phase III ENLIGHT UC study (ES101002) Results in The Lancet Gastroenterology & Hepatology

* The published study results are from the ENLIGHT UC study (ES101002), a multicenter, randomized, double-blind and placebo-controlled Phase III trial of etrasimod conducted acrossAsia. The study included a 12-week induction phase followed by a 40-week maintenance phase and represents the large...

2025-10-09 13:10 1156

Driving Veterinary Healthcare Forward: Anbio Showcases Diagnostic Portfolio at WSAVA 2025

RIO DE JANEIRO, Oct. 8, 2025 /PRNewswire/ -- Anbio Biotechnology participated in the 50th World Small Animal Veterinary Association Congress (WSAVA 2025), an international gathering that brought together veterinarians, researchers, and industry representatives from more than 100 countries. The ev...

2025-10-09 11:41 644

Neopharma Technologies Appoints Singapore Fintech Veteran and Serial Entrepreneur Mr. Joo Seng Wong as Board Advisor to Oversee Institutional Strategy and Global Execution

SINGAPORE, Oct. 8, 2025 /PRNewswire/ -- Neopharma Technologies Ltd ("Neopharma"), a digital health company pioneering AI-driven Digital Drug and Impairment Testing, today announced the appointment of Mr.Joo Seng Wong to its Advisory Board. Mr. Wong will play a key role in strengthening Neopharma'...

2025-10-09 09:58 1075

Breakthrough Lectures to Headline the 2025 World Congress of Neurology in Seoul

SEOUL, South Korea, Oct. 9, 2025 /PRNewswire/ -- The World Federation of Neurology (WFN) and the Korean Neurological Association (KNA) will host the XXVII World Congress of Neurology

2025-10-09 04:41 1051

TCI Biotech Releases 2024 ESG Report, Showcasing Brand Transformation, Global Sustainability Commitments, and Award-Winning Impact

SALT LAKE CITY, Oct. 8, 2025 /PRNewswire/ -- TCI Biotech, a global biotechnology leader in health and wellness, today announced the release of its 2024 Environmental, Social, and Governance (ESG) Report, marking a milestone year of brand renewal, international sustainability recognition, and meas...

2025-10-08 23:00 1021

C-Ray Therapeutics (Shanghai) Co., Ltd. Presents Breakthrough Clinical Data of Novel Targeted Alpha Therapy 225Ac-PSMA-CY313 at EANM 2025

BARCELONA, Spain, Oct. 8, 2025 /PRNewswire/ -- During the 2025 Annual Congress of the European Association of Nuclear Medicine (EANM 2025), C-Ray Therapeutics (Shanghai) Co., Ltd. ("C-Ray Shanghai"), a company dedicated to the development of innovative targeted radiopharmaceuticals, announced pro...

2025-10-08 22:20 1058

India's No: 1 Ranked Institute, IIT Madras & Danish University Study reveals Genetic 'Switches' that can transform Disease Research

CHENNAI, India, Oct. 8, 2025 /PRNewswire/ -- India's No:1 Ranked Institute, the Indian Institute of Technology Madras , and Danish researchers have shown how interactions between genetic variants can act like 'switches' to unlock hidden cellular pathways.

2025-10-08 21:48 1175

Alpha Fusion and Kobe City Medical Center General Hospital Establish At-211 Investigational Drug Supply System

〜Driving Technology Transfer and Test Manufacturing Following Regulatory Approval to Launch Company-Led af-001 Trial〜 TOKYO, Oct. 8, 2025 /PRNewswire/ -- Alpha Fusion Inc. (Alpha Fusion) is proud to announce a joint initiative with the Kobe City Medical Center General Hospital (KCGH) to establis...

2025-10-08 21:00 1105

Covation Biomaterials Highlights Milestones for CovationBio® bioPTMEG at K-Show 2025

DUSSELDORF, Germany, Oct. 8, 2025 /PRNewswire/ -- Covation Biomaterials LLC ("CovationBio® "), a biomaterials company with advanced technology in the bio-based materials industry, is excited to share project milestones and updates for their newest innovation, CovationBio® bioPTMEG at K 2025, the ...

2025-10-08 16:06 1361

CARsgen Presents Results on GPRC5D CAR-T CT071 in The Lancet Haematology

SHANGHAI, Oct. 7, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announces that the results of CT071 (an autologous CAR T-cell product targeting GPRC5D) for the treatment of relapsed/refractory mul...

2025-10-08 08:15 1293

Cyteph Completes Recruitment for Phase I Clinical Trial of CYT-101 in Patients with Recurrent Glioblastoma Multiforme Brain Cancer

BRISBANE, Australia, Oct. 8, 2025 /PRNewswire/ -- Cyteph Pty Ltd , a biotechnology company developing novel immunotherapies for difficult-to-treat cancers, today announced that it has successfully completed recruitment for its first-in-humanPhase I clinical trial of CYT-1...

2025-10-08 06:00 1255

Celaid Therapeutics Raises JPY 1.055 Billion (USD 7.2 Million) in the First Close of its Series B Financing

TOKYO, Oct. 7, 2025 /PRNewswire/ -- Celaid Therapeutics Inc. ("Celaid"), today announced the successful completion of the 1st Close of its Series B financing round, raisingJPY 1.055 billion (USD 7.2 million) from venture capital firms and the Japan Agency for Medical Research and Development (AME...

2025-10-07 21:00 1420
1 ... 12131415161718 ... 341